Clinical Trials Browser

Phase 2 × dalotuzumab × Breast × Clear all

NCT01605396 2019-03-25

MK-8669-064

Phase 2 Completed

80 enrolled 13 charts

Breast Neoplasms

NCT01234857 2017-05-31

A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3)

Phase 2 Completed

Breast Neoplasms